Types and Doses of ARBs
Eight ARBs are clinically available with distinct dosing regimens, ranging from azilsartan 40-80 mg daily to eprosartan 600-800 mg daily, all administered once or twice daily for hypertension management. 1
Available ARB Agents and Standard Dosing
The following ARBs are approved for clinical use with their usual dose ranges 1, 2, 3:
Primary ARB Options
- Azilsartan: 40-80 mg once daily
- Candesartan: 8-32 mg once daily
- Eprosartan: 600-800 mg once or twice daily
- Irbesartan: 150-300 mg once daily
- Losartan: 50-100 mg once or twice daily
- Olmesartan: 20-40 mg once daily
- Telmisartan: 20-80 mg once daily
- Valsartan: 80-320 mg once daily
Target Doses for Heart Failure
For patients with heart failure with reduced ejection fraction (HFrEF), target doses differ from hypertension management and should be uptitrated to evidence-based levels. 4, 5
HFrEF Target Dosing
- Candesartan: Target 32 mg once daily (mean achieved in trials: 24 mg daily) 4
- Losartan: Target 100-150 mg once daily (mean achieved: 129 mg daily) 4, 5
- Valsartan: Target 160 mg twice daily (320 mg total daily; mean achieved: 254 mg daily) 4
At minimum, patients with HFrEF should receive at least 50% of the target dose unless not tolerated (e.g., candesartan 16 mg, losartan 50 mg, valsartan 160 mg total daily). 5
Key Clinical Considerations
Dosing Frequency and Duration of Action
Telmisartan, valsartan, candesartan, and irbesartan provide 24-hour blood pressure control with once-daily dosing, while losartan at standard doses (25-50 mg) has insufficient duration of action. 6 The morning-to-evening effect ratio for losartan (0.49/0.16) demonstrates inadequate trough coverage compared to telmisartan (0.88/0.88), candesartan (0.69/1.01), and valsartan (0.82/0.88). 6
Receptor Binding Characteristics
Candesartan and irbesartan exhibit insurmountable (non-competitive) antagonism at the AT₁ receptor with longer dissociation times, while losartan, valsartan, and eprosartan are competitive antagonists. 7, 8 Candesartan has the highest receptor affinity among all ARBs. 8
Comparative Efficacy
Olmesartan and telmisartan demonstrate superior blood pressure reduction compared to other ARBs, with olmesartan ranking highest for both office blood pressure reduction and safety profile. 9 Valsartan and losartan are less effective at lowering blood pressure than other agents in the class. 9
Critical Safety Warnings
Do not combine ARBs with ACE inhibitors or direct renin inhibitors—this combination is potentially harmful and increases risk of hyperkalemia, hypotension, and acute kidney injury without additional benefit. 1, 2, 10
Additional precautions 1, 2, 3:
- Contraindicated in pregnancy (all ARBs)
- Monitor for hyperkalemia, especially with CKD or concurrent potassium-sparing agents
- Risk of acute renal failure in severe bilateral renal artery stenosis
- Avoid in patients with history of angioedema with ARBs
- Patients with prior ACE inhibitor angioedema can receive ARBs after 6-week washout period
Monitoring After Initiation
Recheck patients 2-4 weeks after initiating or uptitrating ARB therapy, monitoring for hyperkalemia or eGFR decline >30%. 11 If significant decline occurs, consider dose reduction or temporary hold with additional evaluation.
Prodrug Considerations
Candesartan cilexetil and azilsartan medoxomil are prodrugs requiring conversion to active forms. 7 Candesartan cilexetil undergoes complete conversion during gastrointestinal absorption, while losartan is only partially converted to its active metabolite EXP3174. 8